Detalhe da pesquisa
1.
The role of inflammation in kidney cancer.
Adv Exp Med Biol
; 816: 197-234, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24818725
2.
The Cost of Hope: a candid roundtable discussion.
J Natl Compr Canc Netw
; 11(5 Suppl): 633-5, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23704231
3.
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma.
J Clin Oncol
; 41(11): 1965-1971, 2023 04 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37018919
4.
Improvement in overall survival of patients with advanced renal cell carcinoma: prognostic factor trend analysis from an international data set of clinical trials.
J Urol
; 188(6): 2095-100, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23083849
5.
A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.
Invest New Drugs
; 30(1): 266-72, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20697774
6.
A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma.
Invest New Drugs
; 30(1): 364-7, 2012 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20711630
7.
Phase I/II trial of subcutaneous interleukin-2, granulocyte-macrophage colony-stimulating factor and interferon-α in patients with metastatic renal cell carcinoma.
BJU Int
; 109(1): 63-9, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21244601
8.
Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities.
Oncologist
; 16(5): 543-53, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21490127
9.
Clinical and immunomodulatory effects of bevacizumab and low-dose interleukin-2 in patients with metastatic renal cell carcinoma: results from a phase II trial.
BJU Int
; 107(4): 562-70, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-20840548
10.
Casein kinase I delta/epsilon phosphorylates topoisomerase IIalpha at serine-1106 and modulates DNA cleavage activity.
Nucleic Acids Res
; 37(2): 382-92, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19043076
11.
Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure.
Clin Genitourin Cancer
; 19(2): 167-175, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33358149
12.
Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.
J Exp Med
; 196(5): 619-28, 2002 Sep 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-12208877
13.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med
; 356(2): 115-24, 2007 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-17215529
14.
Sorafenib in advanced clear-cell renal-cell carcinoma.
N Engl J Med
; 356(2): 125-34, 2007 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-17215530
15.
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Oncology
; 78(5-6): 340-7, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20733337
16.
RANK ligand: effects of inhibition.
Curr Oncol Rep
; 12(2): 80-6, 2010 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20425591
17.
Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.
J Immunol
; 181(11): 7721-7, 2008 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19017961
18.
Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients.
Clin Cancer Res
; 15(6): 2148-57, 2009 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19276286
19.
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Clin Cancer Res
; 15(7): 2552-8, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19318484
20.
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.
Lancet Oncol
; 10(8): 757-63, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19615940